Facebook
Twitter
LinkedIn
Forward
Overcoming Barriers to Effective Treatment and Enrollment in Clinical Trials for Black and Underserved Patients with Multiple Myeloma
NOTE: If you are a Pharmacist or Physician Associate, please click here to participate in the activity for your credit type.
Multiple myeloma (MM) is one of the most common hematologic malignancies in adults and is the most common hematologic malignancy in black patients. The incidence of MM in the black population is 2-3 times higher than in white patients however, the vast majority of MM clinical trials are conducted on a predominantly white population, resulting in a lack of data regarding MM treatment in black patients.
Our panel of expert Hematology/Oncology faculty convened a patient focus group-informed interactive video discussion emphasizing the treatment and clinical research disparities among black and underserved patients. The focus groups were comprised of diverse groups of MM patients currently being treated at Boston Medical Center.
The goals of our educational program are to address existing knowledge gaps related to the racial disparities which impact MM therapy and clinical trial inclusion; highlight ongoing inequities; and provide guidance so that healthcare clinicians can more effectively and equitably treat patients with MM.
Target Audience
This activity has been designed to meet the educational needs of hematology and oncology physicians, nurses, NPs, PAs, and pharmacists involved in the diagnosis and treatment of patients with multiple myeloma.
Learning Objectives
At the conclusion of this activity, participants will be able to:
- Discuss health inequities and racial disparities in multiple myeloma.
- Describe racially unique adverse drug events associated with treatment for black patients with multiple myeloma.
- Discuss multiple myeloma treatment risks with black patients to support shared decision-making regarding treatment and manage expectations.
- Develop strategies to mitigate the multiple barriers to clinical trial enrollment and appropriate clinical care in black and underserved patients with multiple myeloma.
- Identify appropriate use of BCMA-targeted therapies for all patient populations with multiple myeloma.
Supporters
This activity is supported by independent medical education grants from Bristol Myers Squibb, Karyopharm Therapeutics, Pfizer Inc. and Regeneron Pharmaceuticals, Inc. This activity is also supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Additional Information
| Attachment | Size |
|---|---|
 Multiple Myeloma Slide Set PDF.pdf | 3.01 MB |
Speakers
Frances (Blevins) Arters, PA-C
Department of Medicine
Section of Hematology & Medical Oncology
Boston Medical Center
Assistant Professor
Boston University Chobanian & Avedisian School of Medicine
Boston, Massachusetts
Ajay K. Nooka, MD, MPH, FACP
Medical Director, Winship Data and Technology Applications Shared Resource
Winship Cancer Institute
Professor, Department of Hematology and Medical Oncology
Emory University School of Medicine
Atlanta, Georgia
Bhavesh Shah, RPh, BCOP
Chief Pharmacy Officer
Hematology/Oncology and Specialty Pharmacy
Boston Medical Center Health System
Boston, Massachusetts
Raphael E. Szalat, MD, PhD
Program Course Director
Director, Multiple Myeloma Program
Section of Hematology & Medical Oncology
Department of Medicine
Boston Medical Center
Assistant Professor of Medicine
Boston University Chobanian & Avedisian and School of Medicine
Boston, Massachusetts
Accreditor Disclosure Policy
Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian & Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships with ineligible companies that faculty, planners, authors and anyone who may be in control of content have been mitigated.
Program Faculty Disclosures
Ms. Arters is on an advisory board for Rigel.
Dr. Nooka is a consultant for Adaptive, Amgen, Beyond Springs, Bristol Meyer Squibb, GlaxoSmithKline, Janssen, Karyopharm, Oncopeptides, Pfizer, Sanofi, Secura Bio, and Takeda. He also receives grant/research support from Aduro, Arch Oncology, Amgen, Bristol Meyer Squibb, Genentech, GlaxoSmithKline, Janssen, Karyopharm, KITE and Takeda.
Dr. Shah receives grant/research support from Alexion, Astrazeneca, Pfizer and Rigel.
Dr. Szalat has no relevant financial relationships to disclose.
Off-Label Discussion
The faculty members do not plan on discussing unlabeled/investigational uses of a commercial product.
Accreditor Disclosures
The following planning committee members have no relevant financial relationships to disclose:
Michael Burk, BS, Senior Program Manager, Boston University Chobanian & Avedisian School of Medicine Center for Continuing Education.
Christopher Drury, PhD, Consultant Medical Editor, The Quill Consulting
Jessica Jeune, RN, Nurse Course Advisor, Planning Committee, Boston Medical Center
Natalie Sanfratello, MPH, CHCP, Senior Program Manager, Boston University Chobanian & Avedisian School of Medicine Center for Continuing Education
Disclaimer
THIS CONTINUING EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED. IN NO EVENT SHOULD INFORMATION IN THE MATERIALS REGARDING LAWS, REGULATIONS, OR LEGAL LIABILITY BE CONSIDERED LEGAL ADVICE OR USED AS A SUBSTITUTE FOR CONSULTING WITH AN ATTORNEY.
Joint Accreditation
In support of improving patient care, Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
Boston University Chobanian & Avedisian School of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Nursing Contact Hours: 1, all of which is eligible for pharmacology credit.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 ANCC
- 1.00 ANCC Pharmacology
- 1.00 Participation